New Immunotherapy and Radiation for Colorectal Cancer Spread to the Liver

Plain-English translation of NCT07544784 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether cadonilimab (AK104), a new type of immunotherapy medication, combined with radiation therapy, works better when added to standard chemotherapy for colorectal cancer that has spread to the liver. The study compares patients who receive the new medication plus radiation and standard chemotherapy with patients who receive standard chemotherapy alone. Researchers want to see if this treatment helps more patients live longer and shrink their cancers.

Colorectal cancer that spreads to the liver is serious and difficult to treat. Currently, standard chemotherapy is the main first-line treatment, but it doesn't work well enough for all patients. This medication is designed to help your immune system fight cancer cells more effectively, and combining it with radiation may improve outcomes.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with colorectal cancer that has spread to your liver
you have not received chemotherapy or other cancer treatments yet (or you had surgery for colorectal cancer that came back, but haven't had treatment in at least 6 months)
you are in good enough health to tolerate treatment (performance status 0-1)
your blood counts and organ function are adequate based on recent lab tests

You likely don't qualify if…

you have had cancer in the past 3 years other than skin cancer or cervical cancer in situ
you have active brain metastases or symptomatic metastases in your brain
you have previously received immunotherapy drugs targeting the PD-1, PD-L1, or CTLA-4 pathways
you have an active autoimmune disease or a history of serious autoimmune disease that could be triggered by immunotherapy
you have current lung disease, pulmonary fibrosis, or prior radiation pneumonitis

What participation looks like

If you are in the experimental group, you will receive the new immunotherapy medication cadonilimab combined with radiation therapy to your liver lesions plus standard chemotherapy. If you are in the control group, you will receive standard chemotherapy alone. You will have regular clinic visits for monitoring, blood tests, and imaging scans to see how well the treatment is working. The study involves 73 patients total at a single center in China.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

China

Wenhua Li, Shanghai